International Journal of Hematology

, Volume 92, Issue 2, pp 219–230 | Cite as

Pathogenesis of diffuse large B cell lymphoma

Progress in Hematology Molecular, cellular biology and treatment of B-cell lymphoma

Abstract

Substantial additional insight has been obtained in the past decade regarding the pathogenesis of diffuse large B cell lymphoma (DLBCL). Distinct subtypes of DLBCL have been defined by gene expression profiling (GEP) and they differ not only in GE profiles but also in the pattern of genetic abnormalities. The ability to correlate corresponding genetic and GEP data markedly facilitates the identification of target genes in regions with copy number abnormalities. Oncogenic pathways are often differentially activated in these different subtypes of DLBCL, suggesting that therapy should be targeted according to these differences. The tumor microenvironment plays a significant role in determining outcome and may be a novel target for therapy. The role of microRNA in lymphomagenesis is increasingly being recognized and mutation of key genes has been demonstrated to drive the activation of the NF-κB pathway and B cell receptor signaling. The pace of discovery will be even more rapid in the near future with the convergence of data from multiple complementary genome-wide studies and technological innovations including the rapid advance in the technology of high-throughput sequencing.

Keywords

Diffuse large B-cell lymphoma Pathogenesis Oncogenic pathways 

References

  1. 1.
    Swerdlow SH, Campo E. WHO classification: pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008.Google Scholar
  2. 2.
    Iqbal J, Liu Z, et al. Gene expression profiling in lymphoma diagnosis and management. Best Pract Res Clin Haematol. 2009;22(2):191–210.CrossRefPubMedGoogle Scholar
  3. 3.
    Ishkanian AS, Malloff CA, et al. A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet. 2004;36(3):299–303.CrossRefPubMedGoogle Scholar
  4. 4.
    Bea S, Zettl A, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005;106(9):3183–90.CrossRefPubMedGoogle Scholar
  5. 5.
    Lenz G, Wright GW, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA. 2008;105(36):13520–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Mardis ER, Wilson RK. Cancer genome sequencing: a review. Hum Mol Genet. 2009;18(R2):R163–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol. 2008;26(10):1135–45.CrossRefPubMedGoogle Scholar
  8. 8.
    Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33.CrossRefPubMedGoogle Scholar
  9. 9.
    Sharp PA. The centrality of RNA. Cell. 2009;136(4):577–80.CrossRefPubMedGoogle Scholar
  10. 10.
    Shivdasani RA. MicroRNAs: regulators of gene expression and cell differentiation. Blood. 2006;108(12):3646–53.CrossRefPubMedGoogle Scholar
  11. 11.
    Eis PS, Tam W, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA. 2005;102(10):3627–32.CrossRefPubMedGoogle Scholar
  12. 12.
    Garzon R, Volinia S, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008;111(6):3183–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Malumbres R, Sarosiek KA, et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood. 2009;113(16):3754–64.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhang J, Jima DD, et al. Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood. 2009;113(19):4586–94.CrossRefPubMedGoogle Scholar
  15. 15.
    Zhang L, Huang J, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA. 2006;103(24):9136–41.CrossRefPubMedGoogle Scholar
  16. 16.
    Alizadeh AA, Eisen MB, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11.CrossRefPubMedGoogle Scholar
  17. 17.
    Rosenwald A, Wright G, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–47.CrossRefPubMedGoogle Scholar
  18. 18.
    Rosenwald A, Wright G, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851–62.CrossRefPubMedGoogle Scholar
  19. 19.
    Savage KJ, Monti S, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102(12):3871–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Karnan S, Tagawa H, et al. Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization. Genes Chromosomes Cancer. 2004;39(1):77–81.CrossRefPubMedGoogle Scholar
  21. 21.
    Kobayashi T, Yamaguchi M, et al. Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5− diffuse large B-cell lymphomas. Cancer Res. 2003;63(1):60–6.PubMedGoogle Scholar
  22. 22.
    Niitsu, N., M. Okamoto, et al. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Ann Oncol. 2010Google Scholar
  23. 23.
    Yamaguchi M, Nakamura N, et al. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica. 2008;93(8):1195–202.CrossRefPubMedGoogle Scholar
  24. 24.
    Iqbal J, Sanger WG, et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol. 2004;165(1):159–66.PubMedGoogle Scholar
  25. 25.
    Iqbal J, Greiner TC, et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia. 2007;21(11):2332–43.CrossRefPubMedGoogle Scholar
  26. 26.
    Brandt VL, Roth DB. G.O.D.’s Holy Grail: discovery of the RAG proteins. J Immunol. 2008;180(1):3–4.PubMedGoogle Scholar
  27. 27.
    Deriano L, Stracker TH, et al. Roles for NBS1 in alternative nonhomologous end-joining of V(D)J recombination intermediates. Mol Cell. 2009;34(1):13–25.CrossRefPubMedGoogle Scholar
  28. 28.
    Lee GS, Neiditch MB, et al. RAG proteins shepherd double-strand breaks to a specific pathway, suppressing error-prone repair, but RAG nicking initiates homologous recombination. Cell. 2004;117(2):171–84.CrossRefPubMedGoogle Scholar
  29. 29.
    Tsai AG, Lieber MR. Mechanisms of chromosomal rearrangement in the human genome. BMC Genomics. 2010;11(Suppl 1):S1.CrossRefPubMedGoogle Scholar
  30. 30.
    Peled JU, Kuang FL, et al. The biochemistry of somatic hypermutation. Annu Rev Immunol. 2008;26:481–511.CrossRefPubMedGoogle Scholar
  31. 31.
    Cattoretti G, Mandelbaum J, et al. Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation. Cancer Res. 2009;69(22):8686–92.CrossRefPubMedGoogle Scholar
  32. 32.
    Pasqualucci L, Neumeister P, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412(6844):341–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Liu M, Duke JL, et al. Two levels of protection for the B cell genome during somatic hypermutation. Nature. 2008;451(7180):841–5.CrossRefPubMedGoogle Scholar
  34. 34.
    Lenz G, Nagel I, et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med. 2007;204(3):633–43.CrossRefPubMedGoogle Scholar
  35. 35.
    Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol. 2005;87:163–208.CrossRefPubMedGoogle Scholar
  36. 36.
    Lenz G, Wright G, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313–23.CrossRefPubMedGoogle Scholar
  37. 37.
    Gilmore TD. Role of rel family genes in normal and malignant lymphoid cell growth. Cancer Surv. 1992;15:69–87.PubMedGoogle Scholar
  38. 38.
    Lenz G, Davis RE, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;319(5870):1676–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Compagno M, Lim WK, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459(7247):717–21.CrossRefPubMedGoogle Scholar
  40. 40.
    Honma K, Tsuzuki S, et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood. 2009;114(12):2467–75.CrossRefPubMedGoogle Scholar
  41. 41.
    Hailfinger S, Lenz G, et al. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2009;106(47):19946–51.PubMedGoogle Scholar
  42. 42.
    Dunleavy K, Pittaluga S, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113(24):6069–76.CrossRefPubMedGoogle Scholar
  43. 43.
    Butler MP, Iida S, et al. Alternative translocation breakpoint cluster region 5′ to BCL-6 in B-cell non-Hodgkin’s lymphoma. Cancer Res. 2002;62(14):4089–94.PubMedGoogle Scholar
  44. 44.
    Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol. 2008;8(1):22–33.CrossRefPubMedGoogle Scholar
  45. 45.
    Basso K, Saito M, et al. Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells. Blood. 2010;115(5):975–84.CrossRefPubMedGoogle Scholar
  46. 46.
    Ranuncolo SM, Wang L, et al. BCL6-mediated attenuation of DNA damage sensing triggers growth arrest and senescence through a p53-dependent pathway in a cell context-dependent manner. J Biol Chem. 2008;283(33):22565–72.CrossRefPubMedGoogle Scholar
  47. 47.
    Pasqualucci L, Migliazza A, et al. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood. 2003;101(8):2914–23.CrossRefPubMedGoogle Scholar
  48. 48.
    Saito M, Gao J, et al. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell. 2007;12(3):280–92.CrossRefPubMedGoogle Scholar
  49. 49.
    Cattoretti G, Pasqualucci L, et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell. 2005;7(5):445–55.CrossRefPubMedGoogle Scholar
  50. 50.
    Cerchietti LC, Lopes EC, et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med. 2009;15(12):1369–76.CrossRefPubMedGoogle Scholar
  51. 51.
    Polo JM, Dell’Oso T, et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med. 2004;10(12):1329–35.CrossRefPubMedGoogle Scholar
  52. 52.
    Martins G, Calame K. Regulation and functions of Blimp-1 in T and B lymphocytes. Annu Rev Immunol. 2008;26:133–69.CrossRefPubMedGoogle Scholar
  53. 53.
    Pasqualucci L, Compagno M, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med. 2006;203(2):311–7.CrossRefPubMedGoogle Scholar
  54. 54.
    Tam W, Gomez M, et al. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood. 2006;107(10):4090–100.CrossRefPubMedGoogle Scholar
  55. 55.
    Lam LT, Wright G, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008;111(7):3701–13.CrossRefPubMedGoogle Scholar
  56. 56.
    Melzner I, Bucur AJ, et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood. 2005;105(6):2535–42.CrossRefPubMedGoogle Scholar
  57. 57.
    Mestre C, Rubio-Moscardo F, et al. Homozygous deletion of SOCS1 in primary mediastinal B-cell lymphoma detected by CGH to BAC microarrays. Leukemia. 2005;19(6):1082–4.CrossRefPubMedGoogle Scholar
  58. 58.
    Ilangumaran S, Rottapel R. Regulation of cytokine receptor signaling by SOCS1. Immunol Rev. 2003;192:196–211.CrossRefPubMedGoogle Scholar
  59. 59.
    Ritz O, Guiter C, et al. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood. 2009;114(6):1236–42.CrossRefPubMedGoogle Scholar
  60. 60.
    Shi S, Calhoun HC, et al. JAK signaling globally counteracts heterochromatic gene silencing. Nat Genet. 2006;38(9):1071–6.CrossRefPubMedGoogle Scholar
  61. 61.
    Chen L, Monti S, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111(4):2230–7.CrossRefPubMedGoogle Scholar
  62. 62.
    Gururajan M, Jennings CD, et al. Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J Immunol. 2006;176(10):5715–9.PubMedGoogle Scholar
  63. 63.
    Davis RE, Ngo VN, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88–92.CrossRefPubMedGoogle Scholar
  64. 64.
    Friedberg JW, Sharman J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13):2578–85.CrossRefPubMedGoogle Scholar
  65. 65.
    Young KH, Leroy K, et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood. 2008;112(8):3088–98.CrossRefPubMedGoogle Scholar
  66. 66.
    Young KH, Weisenburger DD, et al. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAIL receptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood. 2007;110(13):4396–405.CrossRefPubMedGoogle Scholar
  67. 67.
    Cheung KJ, Horsman DE, et al. The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target. Br J Haematol. 2009;146(3):257–69.CrossRefPubMedGoogle Scholar
  68. 68.
    Honda R, Yasuda H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J. 1999;18(1):22–7.CrossRefPubMedGoogle Scholar
  69. 69.
    Calin GA, Sevignani C, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 2004;101(9):2999–3004.CrossRefPubMedGoogle Scholar
  70. 70.
    He L, Thomson JM, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435(7043):828–33.CrossRefPubMedGoogle Scholar
  71. 71.
    Xiao C, Srinivasan L, et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol. 2008;9(4):405–14.CrossRefPubMedGoogle Scholar
  72. 72.
    Chang TC, Yu D, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2008;40(1):43–50.CrossRefPubMedGoogle Scholar
  73. 73.
    Takahashi H, Feuerhake F, et al. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes. Clin Cancer Res. 2006;12(11 Pt 1):3265–71.CrossRefPubMedGoogle Scholar
  74. 74.
    Cimmino A, Calin GA, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 2005;102(39):13944–9.CrossRefPubMedGoogle Scholar
  75. 75.
    Moller C, Alfredsson J, et al. Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim. Blood. 2005;106(4):1330–6.CrossRefPubMedGoogle Scholar
  76. 76.
    Dave SS, Fu K, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354(23):2431–42.CrossRefPubMedGoogle Scholar
  77. 77.
    Rimsza LM, Roberts RA, et al. Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood. 2006;107(3):1101–7.CrossRefPubMedGoogle Scholar
  78. 78.
    Roberts RA, Wright G, et al. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood. 2006;108(1):311–8.CrossRefPubMedGoogle Scholar
  79. 79.
    Gross S, Walden P. Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer. Immunol Lett. 2008;116(1):7–14.CrossRefPubMedGoogle Scholar
  80. 80.
    Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27(45):5904–12.CrossRefPubMedGoogle Scholar
  81. 81.
    Dolcetti R, Boiocchi M. Cellular and molecular bases of B-cell clonal expansions. Clin Exp Rheumatol. 1996;14(Suppl 14):S3–13.PubMedGoogle Scholar
  82. 82.
    Pound JD, Gordon J. Maintenance of human germinal center B cells in vitro. Blood. 1997;89(3):919–28.PubMedGoogle Scholar
  83. 83.
    Wiesner M, Zentz C, et al. Conditional immortalization of human B cells by CD40 ligation. PLoS One. 2008;3(1):e1464.CrossRefPubMedGoogle Scholar
  84. 84.
    Gratzinger D, Zhao S, et al. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest. 2008;88(1):38–47.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2010

Authors and Affiliations

  1. 1.Pathology and Microbiology and Center for Leukemia and Lymphoma ResearchUniversity of Nebraska Medical CenterOmahaUSA

Personalised recommendations